- Citations, last 5 years
- 23
- Works, last 5 years
- 6
- h-index
- 17
- Scientists listed
- 1
- Grants since 2016
- 100
Grants received
2016–2023 · research · R44
An Agent-Based Modeling Platform for Environmental Biotechnology
Fatemeh Shirazi · 490 BioTech (United States) · funded by National Institutes of Health
2016–2018 · research · R43
Innovative three-dimensional testicular Co-culture (Mini-Testis) model for reproductive toxicity testing: a pathway based High throughput (HT) and High Content Analysis (HCA)
Lei Yin · 490 BioTech (United States) · funded by National Institutes of Health
2016–2018 · research · R41
An Agent-Based Modeling Platform for Environmental Biotechnology
Mohammad Rk Mofrad · 490 BioTech (United States) · funded by National Institutes of Health
2016–2019 · contract · N01
IGF::OT::IGF VITA 2 - DEVELOPING AN ANTI-THROMBOTIC MONOCLONAL ANTIBODY (MAB) WITH IMPROVED SAFETY AND EFFICACY
Glen Gaughan · 490 BioTech (United States) · funded by National Institutes of Health
2016–2019 · research · R44
Development of Percutaneous DLC for Total Cavo-pulmonary Assistance
Stephen R Topaz · 490 BioTech (United States) · funded by National Institutes of Health
2016–2018 · research · R44
Development of Percutaneous DLC for Total Cavo-pulmonary Assistance
Stephen R Topaz · 490 BioTech (United States) · funded by National Institutes of Health
2016–2021 · research · R44
2-Hydroxybenzylamine for the prevention of Alzheimer's disease: Initial evaluation in humans
John A Rathmacher · 490 BioTech (United States) · funded by National Institutes of Health
2016–2023 · research · R44
Three-dimensional testicular cell co-culture model for reproductive toxicity screening
Lei Yin · 490 BioTech (United States) · funded by National Institutes of Health
2016–2019 · contract · N01
DEVELOPING AN ANTI-THROMBOTIC MONOCLONAL ANTIBODY (MAB) WITH IMPROVED SAFETY AND EFFICACY, VITA 2
Glen Gaughan · 490 BioTech (United States) · funded by National Institutes of Health
2016–2020 · research · R44
Three-dimensional testicular cell co-culture model for reproductive toxicity screening
Lei Yin · 490 BioTech (United States) · funded by National Institutes of Health
2015–2021 · research · R44
Expanding the throughput of real-time toxicological screening of cardiac differentiation by expressing a synthetic luciferase/luciferin genetic pathway in iPSCs
Dan Morrison · 490 BioTech (United States) · funded by National Institutes of Health
2015–2022 · research · R44
Expanding the throughput of real-time toxicological screening of cardiac differentiation by expressing a synthetic luciferase/luciferin genetic pathway in iPSCs
Dan Morrison · 490 BioTech (United States) · funded by National Institutes of Health
2015–2021 · research · R44
Development of a high-throughput screen to detect the effects of both pre- and post-biotransformed compounds for enhanced content drug discovery workflows
Gary S Sayler · 490 BioTech (United States) · funded by National Institutes of Health
2015–2020 · research · R42
Expressing humanized bacterial luciferase in stem cells: Moving beyond fireflyluciferase to expand the informational capacity of animal models for regenerativemedicine
Dan Morrison · 490 BioTech (United States) · funded by National Institutes of Health
2014–2022 · research · R44
Development of a TransApical to Aorta Double Lumen Cannula for a Neonate LVAD
Stephen R Topaz · 490 BioTech (United States) · funded by National Institutes of Health
2014–2020 · research · R44
Development of a TransApical to Aorta Double Lumen Cannula for a Neonate LVAD
Stephen R Topaz · 490 BioTech (United States) · funded by National Institutes of Health
2014–2020 · research · R44
Biocatalyst Platform Technology for Enhancing Cometabolic Biodegradation
Fatemeh Shirazi · 490 BioTech (United States) · funded by National Institutes of Health
2014–2022 · research · R44
High-throughput Biocatalyst Manufacturing for Environmental Biotechnology
Fatemeh Shirazi · 490 BioTech (United States) · funded by National Institutes of Health
2012–2023 · research · R44
Development of Novel Compounds for Treatment of Heart Arrhythmias in CPVT
Sandra Lee Shotwell · 490 BioTech (United States) · funded by National Institutes of Health
2010–2021 · research · R44
A therapeutic vaccine for chronic hepatitis B
David R. Milich · 490 BioTech (United States) · funded by National Institutes of Health